Ceribell beats Q1 revenue estimates; lifts 2026 guidance

CeriBell

11/05/2026 21:27

Overview

US neurodiagnostics firm's Q1 revenue rose 29%, beating analyst expectations

Adjusted EPS for Q1 missed analyst expectations as net loss widened

Company raised full-year 2026 revenue guidance to $112-116 mln

Outlook

Ceribell raises 2026 revenue guidance to $112 mln-$116 mln, up 26%-30% over prior year

Company expects CMS final rule on NTAP reimbursement for delirium monitoring in August 2026

Result Drivers

ACCOUNT EXPANSION - Revenue growth was primarily driven by expansion into new accounts and increased adoption within the active account base

HIGHER OPERATING COSTS - Operating expenses increased due to investments in commercial organization, increased headcount, and legal costs related to intellectual property enforcement

Company press release: ID:nGNX4VVpnx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$26.5 mln
$26.09 mln (8 Analysts)
Q1 EPS
Miss
-$0.52
-$0.39 (8 Analysts)
Q1 Net Income
Miss
-$19.7 mln
-$14.66 mln (7 Analysts)
Q1 Gross Profit
$23.1 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Ceribell Inc is $27.00, about 33.7% above its May 8 closing price of $20.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)